SEARCH

SEARCH BY CITATION

References

  • 1
    Iguchi S, Nishi S, Shinbo J et al. Intratubular calcification in a post-renal transplanted patient with secondary hyperparathyroidism. Clin Transplant 2001; 15: 5154.DOI: 10.1034/j.1399-0012.2001.0150s5051.x
  • 2
    Hartmann A, Charania B, Sund S, Holdaas H, Fauchald P, Flatmark A. Interstitial nephritis with extensive calcium deposits as a cause of renal allograft failure. Nephrol Dial Transplant 1991; 6: 984988.
  • 3
    Ferguson RK, Reed DM, Barber KG, Bannett AD, Raja RM. Sodium-losing nephropathy and nephrocalcinosis after transplantation. Am J Kidney Dis 1985; 5: 206210.
  • 4
    Zazgornik J, Biesenbach G, Grafinger P et al. Rapid calcification of the renal graft in a 38-year old woman with type 1 diabetes. Nephrol Dial Transplant 1996; 11: 545547.
  • 5
    Leapman SB, Vidne BA, Butt KM, Waterhouse K, Kountz SL. Nephrolithiasis and nephrocalcinosis after renal transplantation: a case report and review of the literature. J Urol 1976; 115: 129132.
  • 6
    Daly BD, Goldberg PA, Krebs TL, Wong-You-Cheong JJ, Drachenberg CI. End stage renal transplant failure: allograft appearances on CT. Clin Radiol 1997; 52: 849853.
  • 7
    Boom H, Mallat MJ, De Fijter JW, Paul LC, Bruijn JA, Van Es LA. Calcium levels as a risk factor for delayed graft function. Transplantation 2004; 77: 868873.
  • 8
    Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 23262333.DOI: 10.1056/NEJMoa020009
  • 9
    Mihatsch MJ, Thiel G, Basler V et al. Morphological patterns in cyclosporine-treated renal transplant recipients. Transplant Proc 1985; 17: 101116.
  • 10
    Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria—an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708714.DOI: 10.1034/j.1600-6143.2003.00072.x
  • 11
    Von Kossa J. Ueber die im Organsismus kuenstlich erzeugbaren Verkalkungen. Beitr Pathol Anat Allg Pathol 1901; 29: 163.
  • 12
    Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004; 19: 12811287.DOI: 10.1093/ndt/gfh128
  • 13
    Messa P, Sindici C, Cannella G et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998; 54: 17041713.DOI: 10.1046/j.1523-1755.1998.00142.x
  • 14
    Cundy T, Kanis JA, Heynen G, Morris PJ, Oliver DO. Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med 1983; 52: 6778.
  • 15
    David DS, Sakai S, Brennan BL et al. Hypercalcemia after renal transplantation. Long-term follow-up data. N Engl J Med 1973; 289: 398401.
  • 16
    Alfrey AC, Jenkins D, Groth CG, Schorr WS, Gecelter L, Ogden DA. Resolution of hyperparathyroidism, renal osteodystrophy and metastatic calcification after renal homotransplantation. N Engl J Med 1968; 279: 13491356.
  • 17
    McIntosh DA, Peterson EW, McPhaul JJ Jr. Autonomy of parathyroid function after renal homotransplantation. Ann Intern Med 1966; 65: 900907.
  • 18
    Bonarek H, Merville P, Bonarek M et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 1999; 56: 642649.
  • 19
    Heering P, Degenhardt S, Grabensee B. Tubular dysfunction following kidney transplantation. Nephron 1996; 74: 501511.
  • 20
    Smith KD, Wrenshall LE, Nicosia RF et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14: 10371045.DOI: 10.1097/01.ASN.0000057542.86377.5A
  • 21
    Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996; 50: 11101117.
  • 22
    Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38: 931936.
  • 23
    National Kidney Foundation. NKF K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 6. Serum calcium and calcium-phosphorus product. Internet access: http://www.kidney.org/professionals/kdoqi/index.cfm.
  • 24
    Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant 2004; 19: V15V19.DOI: 10.1093/ndt/gfh1051
  • 25
    National Kidney Foundation. NKF K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 16. Bone disease in the kidney transplant recipient. Internet access: http://www.kidney.org/professionals/kdoqi/index.cfm.
  • 26
    Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827833.DOI: 10.1016/S0140-6736(03)12710-9
  • 27
    Moe SM, O'Neill KD, Duan D et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61: 638647.DOI: 10.1046/j.1523-1755.2002.00170.x
  • 28
    Canfield AE, Farrington C, Dziobon MD et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J Pathol 2002; 196: 228234.
  • 29
    National Kidney Foundation. NKF K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 14. Parathyroidectomy in patients with CKD. Internet access: http://www.kidney.org/professionals/kdoqi/index.cfm.
  • 30
    EBPG Expert Group on Renal Transplantation European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.8. Bone disease. Nephrol Dial Transplant 2002; 17: 4348.DOI: 10.1093/ndt/17.suppl_4.43